Advertisement

Pretargeted Radioimmunotherapy

  • G. Paganelli
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 49)

Keywords

Malignant Glioma Radionuclide Therapy Recurrent Malignant Glioma Anaplastic Astrocytoma Patient Radioimmunoguided Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH (1989) Intratu-moral LAK cell and interleukin-2 therapy of human glioma. J Neurosurg 70:175–182PubMedCrossRefGoogle Scholar
  2. Boiardi A, Salmaggi A, Pozzi A, Broggi G, Silvani A (1996) Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. J Neurooncol 27:157–162PubMedCrossRefGoogle Scholar
  3. Bos ES, Kuijpers WHA, Meesters-Winters M, Pham DT, de Haan AS, van Doornmalen AM, Kaspersen FM, van Boeckel CAA, Gougeoun-Bertrand F (1994) In vitro evaluation of DNA-DNA hybridization as a two step approach in radioimmunotherapy of cancer. Cancer Res 54:3479–3486PubMedGoogle Scholar
  4. Buraggi GL, Callegaro L, Mariani G, Turrin A, Cascinelli N, Attili A, Bom-bardieri E, Terno G, Plassio G, Dovis M (1985) Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: Efficacy of whole immunoglobulin and its F(ab’)2 fragments. Cancer Res 45:3378–3387PubMedGoogle Scholar
  5. Chetanneau A, Barbet J, Peltier P, Le-Doussal JM, Gruaz-Guyon A, Bernard AM, Resche I, Rouvier E, Bourguet P, Delaage M (1994) Pretargeted imaging of colorectal cancer recurrences using an In-111-labelled bivalent hapten and a biospecific antibody conjugate. Nucl Med Commun 15:972–980PubMedGoogle Scholar
  6. Chinol M, Hnatowich DJ (1987) Generator-produced yttrium-90 for radioimmunotherapy. J Nucl Med 28:1465–1470PubMedGoogle Scholar
  7. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman HA, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD (2000) Phase I Trial Results of Iodine-131-labeled antitenascin monoclonal antibody 81c6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862–3872PubMedGoogle Scholar
  8. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133–140PubMedCrossRefGoogle Scholar
  9. Epenetos AA, Munro AJ, Stewart JSW, Rampling R, Lambert HE, McKenzie CG, Soutter WP, Rahemtulla A, Hooker G, Sivolapenko G, Snook D, Courtenay-Luck N, Dhokia B, Krausz T, Taylor-Papadimitriou J, Durbin H, Bodmer WF (1987) Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabelled monoclonal antibodies. J Clin Oncol 5:1890–1899PubMedGoogle Scholar
  10. Fazio F, Paganelli G (1993) Antibody-guided scintigraphy: targeting of the “magic bullet. Eur J Nucl Med 20:1138–1140PubMedCrossRefGoogle Scholar
  11. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W (1988) Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 29:226–234PubMedGoogle Scholar
  12. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212PubMedCrossRefGoogle Scholar
  13. Green NM (1963) Avidin-1. The use of [14C] biotin for kinetic studies and for assay. Biochem J 89:585–591PubMedGoogle Scholar
  14. Hamilton TC, Ozols RF, Longo DL (1987) Biologic therapy for the treatment of malignant common epithelial tumors of the ovary. Cancer 60[Suppl 8]:2054–2063PubMedGoogle Scholar
  15. Hazra DK, Britton KE, Lahiri VL, Gupta AK, Khanna P, Saran S (1995) Immunotechnological trend in radioimmuno-targeting: from “magic bullet” to “smart bomb”. Nucl Med Commun 16:66–75PubMedCrossRefGoogle Scholar
  16. Hirai H (1990) Use of tumor receptors for diagnostic imaging. Acta Radiol 374:57–64Google Scholar
  17. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT (1995) A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 34:121–131PubMedCrossRefGoogle Scholar
  18. Jain RK (1991) Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Bid 60:85–100CrossRefGoogle Scholar
  19. Johnson DA, Baker AL, Laguzza BC, Fix DV, Gutowski MC (1990) Anti-tumor activity of L/1C2-4-desacetylvinblastine-3-carboxyhydrazide im-munoconjugate in xenografts. Cancer Res 50:1790–1794PubMedGoogle Scholar
  20. Kim JA, Triozzi PL, Martin EW (1993) Radioimmunoguided surgery for colorectal cancer. Oncology 7:55–60PubMedGoogle Scholar
  21. Kuhn JA, Corbisiero RM, Buras RR, Carroll RG, Wagman LD, Wilson LA, Yamauchi D, Smith MM, Kondo R, Beatty D (1991) Intraoperative gamma detection probe with presurgical antibody imaging in colon cancer. Arch Surg 126:1398–1403PubMedGoogle Scholar
  22. Larson SM (1985) Radiolabelled monoclonal anti-tumor antibodies and therapy. J Nucl Med 26:538–545PubMedGoogle Scholar
  23. LeDoussal JM, Martin M, Gautherot E, Delaage M, Barbet J (1989) In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30:1358–1366Google Scholar
  24. Leichner PK, Koral KF, Jaszczak RJ, Green AJ, Chen GTY, Roeske JC (1993) An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Physics 20:569–577CrossRefGoogle Scholar
  25. Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, Koch P, Maecke HR, Brancato R, Siccardi AG, Fazio F (1996) Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 37:967–971PubMedGoogle Scholar
  26. Mann BD, Cohen MB, Saxton RE, Morton DL, Benedict WF, Korn EL, Spolter L, Graham LS, Chang CC, Burk MW (1984) Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody. Cancer 54:1318–1327PubMedCrossRefGoogle Scholar
  27. Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scasselati GA, Mal-covati M, Siccardi AG (1988) In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer 2:121–125CrossRefGoogle Scholar
  28. Paganelli G, Magnani P, Zito F, Villa S, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chiolerio F, Seccamani E, Siccardi AG, Fazio F (1991a) Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 51:5960–5966PubMedGoogle Scholar
  29. Paganelli G, Malcovati M, Fazio F (1991b) Monoclonal antibody pretargetting techniques for tumor localization: the avidin-biotin system. Nucl Med Commun 12:211–234PubMedCrossRefGoogle Scholar
  30. Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, Siccardi AG, Fazio F (1992) Two-step tumor targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 19:322–329PubMedCrossRefGoogle Scholar
  31. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, Veronesi U (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348–357PubMedCrossRefGoogle Scholar
  32. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M (2001) Pretargeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227–235PubMedCrossRefGoogle Scholar
  33. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK (2000) Intratumoral administration of recombinant circulary permuted interleukin-4-Pseudomonas Exotoxin in patients with high-grade glioma. Clin Cancer Res 6:2157–2165PubMedGoogle Scholar
  34. Riva P, Franceschi G, Frattarelli M, et al. (1999) Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a Phase I study. Clin Cancer Res 5[Suppl 10]: 3275s–3280sPubMedGoogle Scholar
  35. Schlom J (1986) Basic principles and application of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 46:3225–3238PubMedGoogle Scholar
  36. Strand SE, Zanzonico P, Johnson TK (1993) Pharmacokinetic modeling. Med Physics 20:515–527CrossRefGoogle Scholar
  37. Sung C, van Osdol WW (1995) Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med 36:867–876PubMedGoogle Scholar
  38. Wawrzynczak EJ (1991) Systemic immunotoxin therapy of cancer: advances and prospects. Br J Cancer 64:624–630PubMedGoogle Scholar
  39. Wessels BW, Rogus RD (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11:638–645PubMedCrossRefGoogle Scholar
  40. Wilchek M, Bayer EA (1984) The avidin biotin complex in immunology. Immunol Today 5:39–43CrossRefGoogle Scholar
  41. Wilchek M, Bayer EA (1988) The avidin biotin complex in bioanalytical applications. Anal Biochem 171:1–32PubMedCrossRefGoogle Scholar
  42. Zagzag D, Friedlander DR, Dosik J, Chikramane S, Chan W, Greco MA, Allen JC, Dorovini-Zis K, Grumet M (1996) Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 56:182–189PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • G. Paganelli
    • 1
  1. 1.Division of Nuclear MedicineEuropean Institute of OncologyMilanItaly

Personalised recommendations